Medicare Enrolled
Dr. Kevin Chang, MD
Hematology & Oncology · Oxnard, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Chang from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chang?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Chang
Dr. Kevin Chang is a hematology & oncology specialist in Oxnard, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Chang performed 10,425 Medicare services across 2,857 unique beneficiaries.
Between the years covered by Open Payments, Dr. Chang received a total of $19,806 from 78 pharmaceutical and/or device companies across 709 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Chang is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 29% volume in CA
$19,806 industry payments
Medicare Practice Summary
Medicare Utilization ↗10,425
Medicare services
Top 29% in CA for hematology & oncology
2,857
Unique beneficiaries
$41
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~549 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
3,311 | $8 | $18 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
3,098 | $8 | $30 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
2,135 | $102 | $195 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,043 | $70 | $150 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
268 | $75 | $100 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
160 | $96 | $205 |
| New patient office visit, complex (60-74 min) | 101 | $174 | $375 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
89 | $142 | $395 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
74 | $147 | $250 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
40 | $4 | $25 |
| Principal care management for high-risk disease, first 30 minutes This service involves 30 minutes of personal care management by a qualified healthcare professional for a patient with a single high-risk disease, billed per calendar month. |
30 | $66 | $100 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
25 | $65 | $185 |
| Bone marrow aspiration A procedure to remove a small sample of liquid bone marrow for diagnostic testing. |
17 | $70 | $375 |
| Biopsy of bone marrow | 17 | $145 | $425 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
17 | $125 | $295 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$19,806
Total received (2018-2024)
Avg $2,829/year across 7 years
Top 21% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
78
Companies
709
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$17,226 (87.0%)
Other
Charitable contributions, space rental, and other categories
$1,927 (9.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$653 (3.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,749
2023
$3,698
2022
$2,514
2021
$416
2020
$930
2019
$4,716
2018
$2,783
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,140
AstraZeneca Pharmaceuticals LP
$358
Janssen Biotech, Inc.
$316
ABBVIE INC.
$219
EMD Serono, Inc.
$216
Merck Sharp & Dohme LLC
$204
Astellas Pharma US Inc
$197
Amgen Inc.
$163
Aveo Pharmaceuticals, Inc.
$161
Gilead Sciences, Inc.
$148
BeiGene USA, Inc.
$138
Incyte Corporation
$126
PFIZER INC.
$123
Takeda Pharmaceuticals U.S.A., Inc.
$109
Celgene Corporation
$107
Genentech USA, Inc.
$90
E.R. Squibb & Sons, L.L.C.
$81
Eisai Inc.
$78
SOBI, INC
$72
Agios Pharmaceuticals, Inc.
$62
Alexion Pharmaceuticals, Inc.
$60
TAIHO ONCOLOGY, INC.
$60
Daiichi Sankyo Inc.
$58
Blue Earth Diagnostics Limited
$56
GENZYME CORPORATION
$54
Exelixis Inc.
$42
Regeneron Healthcare Solutions, Inc.
$36
ARRAY BIOPHARMA INC
$32
Dendreon Pharmaceuticals LLC
$30
Genmab U.S., Inc.
$29
Tempus AI, Inc
$27
JAZZ PHARMACEUTICALS INC.
$27
Ipsen Biopharmaceuticals, Inc
$25
Verity Pharmaceuticals Inc.
$24
GlaxoSmithKline, LLC.
$23
Coherus Biosciences Inc.
$21
Kyowa Kirin, Inc.
$20
Pharmacosmos Therapeutics Inc.
$17
Top 3 companies account for 38.2% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$2,143
Novartis Pharmaceuticals Corporation
$1,889
Amgen Inc.
$906
Janssen Biotech, Inc.
$867
Celgene Corporation
$865
Astellas Pharma US Inc
$850
PFIZER INC.
$836
Genentech USA, Inc.
$782
GENZYME CORPORATION
$773
Merck Sharp & Dohme Corporation
$633
Incyte Corporation
$614
E.R. Squibb & Sons, L.L.C.
$547
Merck Sharp & Dohme LLC
$430
Seattle Genetics, Inc.
$421
Takeda Pharmaceuticals U.S.A., Inc.
$406
Pharmacyclics LLC, An AbbVie Company
$383
Alexion Pharmaceuticals, Inc.
$362
EMD Serono, Inc.
$341
GlaxoSmithKline, LLC.
$327
NOVARTIS PHARMACEUTICALS CORPORATION
$299
ADC Therapeutics America, Inc.
$279
TESARO, Inc.
$276
Gilead Sciences, Inc.
$252
ABBVIE INC.
$250
Clovis Oncology, Inc.
$235
Eisai Inc.
$212
AbbVie, Inc.
$209
BeiGene USA, Inc.
$184
Sun Pharmaceutical Industries Inc.
$183
Dendreon Pharmaceuticals LLC
$181
EISAI INC.
$164
Aveo Pharmaceuticals, Inc.
$161
JAZZ PHARMACEUTICALS INC.
$152
Exelixis Inc.
$148
Seagen Inc.
$136
Inari Medical, Inc.
$134
AVEO Pharmaceuticals, Inc.
$130
Regeneron Healthcare Solutions, Inc.
$128
Progenics Pharmaceuticals, Inc.
$112
SOBI, INC
$110
Foundation Medicine, Inc.
$109
Lilly USA, LLC
$109
TAIHO ONCOLOGY, INC.
$105
Rigel Pharmaceuticals, Inc.
$93
AbbVie Inc.
$86
Blue Earth Diagnostics Limited
$74
Karyopharm Therapeutics Inc.
$67
Blueprint Medicines Corporation
$65
Agios Pharmaceuticals, Inc.
$62
Daiichi Sankyo Inc.
$58
AMAG Pharmaceuticals, Inc.
$42
Teva Pharmaceuticals USA, Inc.
$32
ARRAY BIOPHARMA INC
$32
Boehringer Ingelheim Pharmaceuticals, Inc.
$31
Puma Biotechnology, Inc.
$30
Genmab U.S., Inc.
$29
MEDIVATION FIELD SOLUTIONS LLC
$27
Tempus AI, Inc
$27
Ipsen Biopharmaceuticals, Inc
$25
Medtronic USA, Inc.
$25
Mylan Institutional Inc.
$24
Verity Pharmaceuticals Inc.
$24
Bayer HealthCare Pharmaceuticals Inc.
$24
MorphoSys, US Inc.
$24
Taiho Oncology, Inc.
$23
Array BioPharma Inc.
$22
Spectrum Pharmaceuticals Inc.
$22
Myriad Genetic Laboratories, Inc.
$22
Coherus Biosciences Inc.
$21
Verastem, Inc.
$21
Kyowa Kirin, Inc.
$20
Kite Pharma, Inc.
$19
Helsinn Therapeutics (U.S.), Inc.
$19
TOLMAR Pharmaceuticals, Inc.
$17
Chiesi USA, Inc.
$17
Pharmacosmos Therapeutics Inc.
$17
INSYS Therapeutics Inc
$16
Mirati Therapeutics, Inc.
$16
Top 3 companies account for 24.9% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALUNBRIG · AYVAKIT · Abraxane · Alecensa · Aliqopa · Aranesp · Avastin · Axumin · BAVENCIO · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · BYNFEZIA PEN · Balversa · Bavencio · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · COSELA · Cabometyx · Copiktra · Crysvita · DARZALEX · DOPTELET · Doptelet · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · ENHERTU · EPKINLY · ERLEADA · EVENITY · Enhertu · Epkinly · Erleada · FASLODEX · FERAHEME · FERRIPROX · FLOWTRIEVER CATHETER · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · FlowTriever · Folotyn · GAZYVA · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · INREBIC · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · KYPHON Balloon Kyphoplasty · Kyprolis · LIBTAYO · LONSURF · LOQTORZI · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · NINLARO · Nerlynx · Neulasta · Nplate · OPDIVO · OPDUALAG · Ogivri · Onivyde · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POSLUMA · PROMACTA · PROVENGE · PYLARIFY · PYRUKYND · Padcev · Perjeta · Phesgo · REBLOZYL · RYBREVANT · Revlimid · Rubraca · S · SARCLISA · SPRYCEL · SUTENT · SYNDROS · TAGRISSO · TALVEY · TALZENNA · TASIGNA · TECENTRIQ · TECVAYLI · TEPMETKO · TUKYSA · Tavalisse · Tecentriq · Trelstar · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · Venclexta · Vyloy · XALKORI · XOSPATA · XPOVIO · XTANDI · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (87%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
19
Per 100K population
2.3
County median income
$107,327
Nearest hospital
ST JOHNS REGIONAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Chang is a clinical cardiology specialist, with above-average Medicare volume (top 29% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Chang experienced with blood draw (venipuncture)?
Based on Medicare claims data, Dr. Chang performed 3,311 blood draw (venipuncture) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chang receive payments from pharmaceutical companies?
Yes. Dr. Chang received a total of $19,806 from 78 companies across 709 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chang's costs compare to other hematology & oncology specialists in Oxnard?
Dr. Chang's average Medicare payment per service is $41. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chang) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Oxnard
Browse hematology & oncology specialists in Oxnard ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology